By creator to www.nasdaq.com
(RTTNews) – Shares of HOOKIPA Pharma Inc. (HOOK) are down 44 % from their 52-week excessive of $14.38, recorded final April, and commerce round $8.
The Firm made its debut on the Nasdaq International Choose Market on April 18, 2019, by setting a public providing at $14 per share.
HOOKIPA Pharma is a clinical-stage biopharmaceutical firm creating a brand new class of immunotherapeutics focusing on infectious ailments and cancers based mostly on its proprietary arenavirus platform that’s designed to reprogram the physique’s immune system.
The Firm’s lead infectious illness product candidate is HB-101 Prophylactic Vaccine, which is underneath a section II scientific trial in cytomegalovirus-negative sufferers awaiting kidney transplantation from cytomegalovirus-positive donors.
HOOKIPA expects to report security and immunogenicity knowledge within the first half of 2020 from roughly one-third of the overall 150 sufferers to be enrolled, together with placebo recipients within the section II HB-101 trial. The immunogenicity knowledge set will include each CMV-specific antibody (gB) and CMV-specific CD8+ T cell responses.
The preliminary efficacy knowledge is predicted to be reported late within the second half of 2020.
In wholesome individuals, Cytomegalovirus causes solely gentle sicknesses like fever, sore throat, fatigue and swollen glands. However individuals with weakened immune methods who get CMV can have extra severe signs affecting the eyes, lungs, liver, esophagus, abdomen, and intestines. (Supply: CDC).
There is no such thing as a authorised CMV vaccine to stop infections or reactivation. CMV causes vital morbidity and mortality in immunocompromised people, together with strong organ transplant (SOT) recipients and neonates (congenital).
It’s estimated that about 20%-30% or roughly 25,000 SOT recipients develop CMV illness yearly worldwide and about 20,000-30,000 infants are contaminated with the virus yearly within the U.S.
Additionally within the pipeline are the oncology product candidates, HB-201 and HB-202, for the remedy of human papillomavirus-positive cancers.
HB-201 is underneath a section I/II trial, with preliminary outcomes anticipated in late 2020 or early 2021. The Firm plans to judge HB-202 together with HB-201 in HPV16+ cancers, with or with out an authorised checkpoint inhibitor. A section I/II trial evaluating the mixture of HB-201 and HB-202 is predicted to begin later in 2020.
HOOKIPA Pharma has a partnership with Gilead Sciences (GILD) to develop arenavirus based mostly therapeutics for HBV and HIV an infection.
A one-time upfront fee of $10.zero million was obtained by the Firm upon getting into into the settlement in June 2018. Additionally it is entitled to obtain as much as $400 million from Gilead upon the achievement of specified improvement, regulatory, and industrial milestones.
Gathered deficit: $60 million (as of Dec.31, 2019)
Annual income from collaboration and licensing: $11.94 million in 2018 vs. $7.63 million in 2018
Annual internet Loss: $43 million in 2019 vs. $16.24 million in 2018
Money available as of year-end 2019: $113.6 million
HOOK has traded in a spread of $5.80 to $14.38 within the final 1 12 months. The inventory closed Friday’s (Apr.17) buying and selling at $8.05, up 11.34%.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
— to www.nasdaq.com